Targeting Anhedonia in Cocaine Use Disorder
Cocaine-Related Disorders, Anhedonia
About this trial
This is an interventional treatment trial for Cocaine-Related Disorders
Eligibility Criteria
Inclusion Criteria:
- be between 18 and 60 years of age
- meet Diagnostic and Statistical Manual V (DSM-5) criteria for current cocaine use disorder of at least moderate severity (≥ 4 symptoms)
- have at least 1 cocaine positive urine sample during the baseline screening period
- be in acceptable health on the basis of interview, medical history and physical exam, per the judgment of our study physician
- be able to understand the consent form and provide written informed consent
- be able to provide the names of at least 2 persons who can generally locate their whereabouts.
- if female, agree to use an acceptable method of birth control during study (surgical sterilization, approved hormonal contraceptives, barrier methods with spermicide, or intrauterine device).
Exclusion Criteria:
- current DSM-5 diagnosis for substance use disorder of least moderate severity (≥ 4 symptoms), other than cocaine, nicotine, marijuana, or alcohol
- Physical dependence on alcohol requiring medically supervised detoxification, in the judgment of the study physician
- current amphetamine use (by self-report in past 30 days or positive urine drug screen), more than 50 lifetime uses of amphetamine, or history of DSM-5 Amphetamine Use Disorder
- a current DSM-5 axis I psychiatric disorder or neurological disease or disorder requiring ongoing treatment and/or making study participation unsafe
- significant current suicidal or homicidal ideation
- medical conditions contraindicating d-amphetamine (e.g., significant cardiovascular disease, liver or kidney disease, seizure disorder, hypotension or hypertension)
- taking medications known to have effects on the central nervous system or that could cause significant drug interactions with d-amphetamine (e.g., clonidine, prazosin)
- having conditions of probation or parole requiring reports of drug use to officers of the court
- impending incarceration
- pregnant or nursing for female patients
- inability to read, write, or speak English
Additional Exclusion Criteria for the functional magnetic resonance (fMRI) Sub-Study (in addition to all listed criteria above for the Main Treatment Study):
- body mass index (BMI) >30, as this may be incompatible with the magnetic resonance scanner gantry
- any retained metals in the body, including implants and metallic substances (e.g. aneurysm clips, retained metal particles in metal workers, magnetic dental implants, ferromagnetic ocular implants, iron-based facial tattoos), as this may cause adverse effects to participants and interfere with data collection in the MR magnetic field
- inability to tolerate small, enclosed spaces (such as the magnetic resonance scanner bore)
Sites / Locations
- University of Illinois at ChicagoRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Active Comparator
d-Amphetamine and Contingency Management
d-Amphetamine alone
Placebo and Contingency Management
Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine with contingency management treatment for cocaine use disorder.
Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine but will not receive contingency management treatment for cocaine use disorder.
Participants in this group will receive 4 weeks of of placebo treatment, paired with contingency management treatment for cocaine use disorder.